.jpg?width=230&height=32&name=BBRetail001-CMYK%20(1).jpg){kind=small}
The rising demand for GLP-1 medications — widely recognized for their effectiveness in weight management and chronic disease prevention — has created a significant coverage gap in Medicare. Historically, federal law has prohibited Medicare Part D from covering drugs prescribed solely for weight loss. The Medicare GLP-1 Bridge program represents Centers for Medicare & Medicaid Services (CMS)’s first major step toward addressing this gap.
For Medicare stakeholders, including beneficiaries, advisors, and plan sponsors, this short-term demonstration signals a meaningful shift in how high-cost, high-impact therapies may be integrated into the program moving forward.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge program is a CMS-led, short-term demonstration program launching July 1, 2026, and running through December 31, 2027. It is designed to provide eligible Medicare Part D beneficiaries access to select GLP-1 medications for weight management — a category traditionally excluded from coverage.
Importantly, the program functions outside the standard Medicare Part D benefit structure. CMS has established a centralized processing system that handles prior authorization, claims adjudication, and pharmacy payments, rather than relying on individual Part D plans.
The Bridge was originally designed as a transitional step toward the CMS BALANCE Model. However, CMS has since extended the Bridge program through December 31, 2027, while broader Medicare implementation of BALANCE remains under evaluation.
How the CMS GLP-1 Bridge program affects Medicare beneficiaries
Expanded access to eligible GLP-1 medications
For Medicare beneficiaries, the GLP-1 Bridge program represents expanded access — but with important nuances. The Medicare GLP-1 Bridge program is intended for beneficiaries who are not already eligible for GLP-1 coverage through Part D. Those receiving GLP-1 medications for conditions such as diabetes, sleep apnea, or MASH typically remain covered through their existing Medicare drug plan.
Eligible beneficiaries can access certain GLP-1 drugs — such as Wegovy, Zepbound, and Foundayo tablets — specifically for weight management, even though these are not typically covered under Part D. Not all GLP-1 products qualify.
Who is eligible for the CMS GLP-1 Bridge program?
To qualify for GLP-1 eligible beneficiaries must:
- Be enrolled in a Part D or Medicare Advantage prescription drug plan.
- Meet defined BMI clinical criteria:
- Body Mass Index (BMI) ≥35; or
- BMI ≥30 plus heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a or higher; or
- BMI ≥27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease.
- Obtain prior authorization through the CMS-designated processor.
Understanding the GLP-1 Bridge program's cost structure
The GLP-1 Bridge program offers a flat monthly copay of $50, regardless of benefit phase.
Costs that are not included in Medicare Part D spending limits
However, there are important trade-offs:
- Costs do not count toward Part D deductibles or out-of-pocket maximums.
- Subsidies like Extra Help (LIS) do not apply.
- Manufacturer discounts or coupons are not permitted.
For some beneficiaries — particularly those on fixed incomes — these limitations may affect affordability despite the relatively low flat copay.
How the GLP-1 Bridge program differs from Medicare Part D
Beneficiaries will interact with a different administrative system than their standard Part D plan for these medications. This includes:
- Separate prior authorization process.
- Different claims handling.
- Distinct pharmacy billing pathway.
This separation may introduce confusion without proper education and guidance.
How the CMS GLP-1 Bridge program impacts Medicare Part D plans
The GLP-1 Bridge program also has significant implications for Part D plan sponsors — particularly in terms of risk, compliance, and future strategy.
No direct financial responsibility for Part D plans
Because the program operates outside Part D:
- Plans are not responsible for covering the cost of GLP-1 drugs under the Bridge.
- No risk is transferred to plan sponsors for these claims.
This design allows CMS to test expanded access without immediately impacting plan premiums or benefit structures.
Maintaining existing Medicare Part D coverage responsibilities
Part D plans must still:
- Cover GLP-1 drugs for approved indications (e.g., diabetes, cardiovascular conditions).
- Maintain compliance with all existing Medicare requirements.
Plans cannot restrict access or steer beneficiaries toward the Bridge program inappropriately.
Operational considerations for Medicare Part D plans
While plans are not directly involved in administering the Bridge, they must:
- Coordinate with providers and pharmacies navigating dual pathways.
- Prepare for potential data-sharing and future policy changes.
The program also offers CMS an opportunity to collect utilization and cost data, which could influence long-term Part D design and pricing strategies.
Why the CMS GLP-1 Bridge program matters
The GLP-1 Bridge program represents more than a temporary coverage solution — it reflects a broader shift in how Medicare may approach high-cost, high-demand therapies.
Why CMS launched the GLP-1 Bridge program
GLP-1 medications have already driven substantial spending growth in Medicare, highlighting both their clinical impact and financial complexity.
By carving out a separate demonstration:
- CMS can evaluate utilization, outcomes, and affordability.
- Plan sponsors gain insight into future coverage and risk scenarios.
- Beneficiaries receive earlier access to transformative therapies.
Questions that may shape the program's future
The program’s temporary status raises important questions:
- What happens after December 31, 2027?
- Will broader coverage become permanent through models like BALANCE?
- How will costs be integrated into Part D without disrupting premiums?
What Medicare stakeholders can expect
For Medicare stakeholders, the GLP-1 Bridge program is a pivotal development at the intersection of clinical innovation and policy evolution. It expands access in the near term while laying the groundwork for potential long-term change.
- For beneficiaries, it offers new treatment opportunities — but requires careful navigation.
- For Part D plans, it minimizes immediate disruption while signaling future transformation.
As Medicare continues to evolve, programs like the GLP-1 Bridge highlight a central challenge: balancing access, affordability, and sustainability in an era of rapidly advancing therapies.
If you have questions about how the CMS GLP-1 Bridge program may affect your Medicare coverage or would like guidance evaluating your options, connect with a Brown & Brown Medicare specialist.
About the author
Brenda Shearer is the National Director of EB Select and Medicare, dedicated to providing day-to-day employee benefit account management for customers and brokers, as well as the management of the staff. She has extensive training and knowledge of all major carriers in the marketplace, including individual, Medicare, small and large group products. She has also worked closely with large accounts and PEO’s.
Brown & Brown does not offer every plan available in every geographic location. Any information Brown & Brown provides is limited to those plans offered by Brown & Brown. Brown & Brown is not connected nor endorsed by the United States or any state government or Medicare program. Please contact Medicare.gov or 1-800-Medicare to get information on all your options.